Drugs / Subetta
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03725033 | Oct 2018 → Mar 2020 | glucose intolerance | Materia Medica Holding | Completed | Met primary |
| Phase 42 trials · 2 met primary | ||||||
| Phase 4 | NCT01868646 | May 2013 → Jun 2016 | type 2 diabetes mellitus | Materia Medica Holding | Completed | Met primary |
| Phase 4 | NCT01868594 | May 2013 → Jul 2016 | type 1 diabetes mellitus | Materia Medica Holding | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Subetta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01868594 ↗ |
| Action | Activate | “Derived by technological treatment of antibodies to insulin receptor β-subunit and endothelial NO synthase Subetta was previously proved to activate insulin signaling pathway.” PMID 29807102 ↗ May 2018 |
| Modality | Protein / enzyme biologic | “Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced...” NCT01868594 ↗ |
| Route | Oral | “Subetta: oral administration, per 1 intake - 1 tablet” NCT01868594 ↗ |